The acquisition gives Novozymes broader access to the DKK ~40 billion global market for human probiotics supplements
Novozymes has announced the acquisition of Microbiome Labs. Based in the US, Microbiome Labs offers a comprehensive portfolio of proprietary probiotic and microbiome solutions and is a vital player in the consumer health industry. The company is delivering double-digit sales growth in 2020, resulting in a revenue of DKK ~250 million (USD ~40 million) with a positive cash flow and an EBIT margin slightly lower than Novozymes’ EBIT margin.
Said, Ester Baiget, President and CEO of Novozymes, “Probiotics for human use is a selected growth area for Novozymes, and it brings the opportunity of advancing our activities within human health. This is an attractive and relatively young industry and, by acquiring Microbiome Labs, we gain a broader portfolio and a strong position in the North American probiotics market. Combined with our organically developed activities in OneHealth, we ensure a strong foundation for future growth.”
Denmark headquartered Novozymes has established the brand OneHealth to market solutions within human health under one umbrella. The aim is to help people live healthier and better lives by use of probiotics and enzymes.
“Novozymes is the right home for us. We get global market access and world class science to develop new solutions combining enzymes and probiotics to create clinically-proven solutions that improve human health and well-being,” said D. Tom Bayne, CEO at Microbiome Labs.
The acquisition gives Novozymes broader access to the DKK ~40 billion global market for human probiotics supplements and a well-established entry point into the important North American market: a market valued at DKK ~15 billion and expected to grow with a high-single-digit rate over the next 3-5 years.